| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 registrational clinical trials of aleniglipron (oral small molecule GLP-1 receptor agonist) enrolling; topline data expected in 2H 2028 |
| 08 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
2 This presentation contains “forward - looking statements” within the meaning of the “safe harbor” provisions of the Private Securi ties Litigation Reform Act of 1995. All statements other than statements of historical fact are statemen... |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
First patients dosed in aleniglipron (oral small molecule GLP-1 receptor agonist) Phase 3 ACCOMPLISH program for chronic weight management |
| 18 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 17, 2026, Structure Therapeutics Inc. (the “Company”) held its 2026 Annual General Meeting of Shareholders (the “Annual General Meeting”). As of April 20, 2026, the record date for the Annual General Meeting, 213,213,565 ordinary... |
| 07 May 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more
Reference is made to that certain Sales Agreement, entered into as of August 6, 2025 (the “Original Sales Agreement”), by and among Structure Therapeutics Inc., an exempted company with limited liability incorporated under the laws of th... |
| 15 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
SAN FRANCISCO, April 14, 2026 – Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announ... |
| 16 Mar 2026 |
8-K: Regulation FD Disclosure; Other Events
1 March 16, 2026 Aleniglipron Topline ACCESS II and Supplementary Studies |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition
Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks |
| 05 Jan 2026 |
8-K: Entry into a Material Definitive Agreement
On December 30, 2025, Gasherbrum Bio, Inc. (“Gasherbrum”), a wholly-owned subsidiary of Structure Therapeutics Inc. (the “Company”), entered into an agreement (the “GNE Agreement”) with Genentech, Inc. (“Genentech”) and F. Hoffmann-La Ro... |
| 10 Dec 2025 |
8-K: Other Events
Introductory. Structure Therapeutics Inc., an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Und... |
| 08 Dec 2025 |
8-K: Regulation FD Disclosure; Other Events
1 December 8, 2025 Aleniglipron Topline ACCESS Phase 2b Results |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025 |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition
Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts |
| 25 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 23, 2025, Structure Therapeutics Inc. (the “Company”) held its 2025 Annual General Meeting of Shareholders (the “Annual General Meeting”). As of April 17, 2025, the record date for the Annual General Meeting, 172,610,249 ordinary... |
| 08 May 2025 |
8-K: Results of Operations and Financial Condition
Topline data from oral small molecule aleniglipron (GSBR-1290) Phase 2b ACCESS and ACCESS II studies anticipated by year-end 2025 |
| 27 Feb 2025 |
8-K: Results of Operations and Financial Condition
Aleniglipron (GSBR-1290) ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025 |
| 17 Dec 2024 |
8-K: Regulation FD Disclosure
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity |
| 13 Nov 2024 |
8-K: Results of Operations and Financial Condition
Oral small molecule amylin receptor agonist development candidate |
| 17 Sep 2024 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure +1 more
Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer |
| 27 Aug 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Loading...